Personalis (NASDAQ:PSNL) Price Target Raised to $16.25

Personalis (NASDAQ:PSNL) had its price target raised by BTIG Research from $11.00 to $16.25 in a report released on Monday, MarketBeat Ratings reports. They currently have a buy rating on the stock.

Several other equities analysts have also recently weighed in on PSNL. Needham & Company LLC cut shares of Personalis from a “buy” rating to a “hold” rating in a research note on Monday. Lake Street Capital cut shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Morgan Stanley boosted their price objective on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Finally, TD Cowen restated a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $14.25.

Personalis Stock Performance

Personalis stock opened at $12.47 on Monday. Personalis has a one year low of $3.84 and a one year high of $16.39. The stock has a fifty day moving average of $11.36 and a 200 day moving average of $9.01. The stock has a market cap of $1.31 billion, a PE ratio of -12.23 and a beta of 2.24.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The firm had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. As a group, sell-side analysts predict that Personalis will post -1.07 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Aaron Tachibana sold 4,982 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $14.00, for a total value of $69,748.00. Following the completion of the sale, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at $2,783,662. This represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the sale, the chief executive officer owned 235,986 shares in the company, valued at $3,558,668.88. The trade was a 29.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 435,032 shares of company stock worth $5,599,929. 4.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PSNL. T. Rowe Price Investment Management Inc. increased its stake in Personalis by 273.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after buying an additional 7,896,714 shares in the last quarter. Aberdeen Group plc raised its holdings in Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after acquiring an additional 861,948 shares during the period. Kennedy Capital Management LLC lifted its position in shares of Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after acquiring an additional 1,281,695 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Personalis by 1,332.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after acquiring an additional 1,347,439 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Personalis by 11.0% in the third quarter. Millennium Management LLC now owns 1,210,754 shares of the company’s stock worth $7,894,000 after acquiring an additional 120,027 shares during the period. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.